Craniosynostoses: Clinical Trials

7 trials for Craniosynostoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7
Phase 11Completed 1

Follow Craniosynostoses: new trials by email Literature Review of Craniosynostoses trials Research Report on Craniosynostoses

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Pemigatinib - Non-Small Cell Lung Cancer (NSCLC)
Phase 2CompletedIncyte Corporation82022-04-292025-08-05
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
E7090 - Cholangiocarcinoma
Phase 2CompletedEisai Co., Ltd.632020-01-222026-03-02
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Rogaratinib (BAY1163877), Combination drug - Cancer
Phase 2CompletedBayer12019-10-302022-04-01
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma
Phase 1 / Phase 2CompletedBasilea Pharmaceutica952019-08-022023-10-13
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Pemigatinib - Cholangiocarcinoma
Phase 2CompletedIncyte Corporation1472017-01-162025-08-14
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
pemigatinib - UC (Urothelial Cancer)
Phase 2CompletedIncyte Corporation2632017-01-122025-08-14
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Erdafitinib - Neoplasm
Phase 2CompletedJanssen Research & Development, LLC352016-07-082025-04-27

Narrower conditions

Acrocephalosyndactylia (7)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Carcinoma, Transitional Cell (3)  ·  Cholangiocarcinoma (3)  ·  Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Recurrence (1)  ·  Small Cell Lung Carcinoma (1)  ·  Urinary Bladder Neoplasms (1)

Broader conditions

Bone Diseases (7)  ·  Bone Diseases, Developmental (7)  ·  Congenital Abnormalities (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Craniofacial Abnormalities (7)  ·  Dysostoses (7)  ·  Limb Deformities, Congenital (7)  ·  Musculoskeletal Abnormalities (7)  ·  Musculoskeletal Diseases (7)  ·  Syndactyly (7)  ·  Synostosis (7)  ·  Carcinoma (6)  ·  Neoplasms by Histologic Type (6)  ·  Neoplasms, Glandular and Epithelial (6)

Interventions

pemigatinib (3)  ·  Drug Combinations (1)  ·  INCB 54828-101 (1)  ·  Rogaratinib (1)  ·  atezolizumab (1)  ·  derazantinib (1)  ·  erdafitinib (1)

Sponsors

Incyte Corporation (3)  ·  Basilea Pharmaceutica (1)  ·  Bayer (1)  ·  Eisai Co., Ltd. (1)  ·  Janssen Research & Development, LLC (1)

Countries

France (4)  ·  Germany (4)  ·  Italy (4)  ·  Spain (4)  ·  United States (4)  ·  Japan (3)  ·  South Korea (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  China (2)  ·  Israel (2)  ·  Switzerland (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Austria (1)

Top investigators

Ekaterine Asatiani, MD (1)  ·  Luisa Veronese, MD (1)

Results publications

PMID 32203698, PMID 35544727, PMID 36206041, PMID 37956738, PMID 38039831, PMID 38627238, PMID 39138436

NIH funding

2016 (2), 2019 (2)